Log in Request access

Caplight Directory

ID SOLUTIONS

Montpellierid-solutions.fr

Overview

ID SOLUTIONS is a French company specializing in the development of molecular biology solutions for research and diagnostics in human oncology and infectious diseases, which also makes strategic investments.

Year Founded

2016

Portfolio Companies

1

Website

id-solutions.fr

Investments

Company	Date	Stage	Lead
Oncobit	Nov 2025	Early Funding	Co-investor

Sector & Stage Mix

Industry, funding stage, and valuation band breakdowns.

Premium

SeedSeries ASeries BGrowth

Unlock portfolio analytics

Sign up to view full sector, stage, and valuation breakdowns for this investor.

Investment Activity

Yearly cadence, pace, and funding raised over time.

Premium

2021

2022

2023

2024

2025

2026

Unlock portfolio analytics

Sign up to explore yearly investment trends and funding raised over time.

FAQ

Firmographic Details

HeadquartersMontpellier

Year Founded2016

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

Use CasesInvestors Employees

CompaniesAll Companies

LegalPrivacy Policy Terms of Use BrokerCheck Form CRS

Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.